Altunan, BengüEfendi, HüsnüKöseoğlu, MesrureTerzi, MuratKotan, DilcanTamam, YusufÜnal, Aysun2023-08-182023-08-182023Altunan, B., Ünal, A., Efendi, H., Köseoğlu, M., Terzi, M., Kotan, D. ve diğerleri. (2023).Use of follow-on fingolimod for multiple sclerosis: Analysis of effectiveness and patient reported outcomes in a real-world clinical setting. Multiple Sclerosis and Related Disorders, (77), 1-7.2211-0348https://www.sciencedirect.com/science/article/pii/S2211034823003814?via%3Dihubhttps://hdl.handle.net/11468/12503Background: Follow-on disease modifying therapies (FO-DMTs) do not always require Phase III studies. There are concerns that cheaper FO-DMTs are only used to reduce healthcare costs. However, the well-being of people with MS (pwMS) should be a priority. We aimed to evaluate the efficacy, safety and treatment satisfaction of one of the FO- Fingolimod (FTY) used in Turkey with the approval of Turkish Ministry of Health. Methods: PwMS under FTY were recruited from 13 centers and real-world data and answers of satisfaction and adherence statements of pwMS on FTY treatment were analyzed. Results: Data of 239 pwMS were obtained. The duration of FTY treatment was 2.5 ± 0.8 (1–4) years in pwMS who were included in the study and whose treatment continued for at least one year. Significant decreases in annual relapse rate (p < 0.001), Expanded Disability Status Scale (p < 0.001) and neuroimaging findings (p < 0.001) were observed. While 64% of the patients were satisfied and 71.5% were found to adherent with this FO-FTY. Conclusion: This multicenter retrospective study found that the efficacy, safety and treatment adherence of a prescribed FO-FTY were consistent with the results of real-world studies. Studies including real-world data may provide guidance to address issues related to FO-FTY use.eninfo:eu-repo/semantics/closedAccessFollow-on drugGeneric fingolimodReal-world dataEfficacySafetySatisfactionAdherenceArticle7717WOS:0010397584000012-s2.0-851652510463745971610.1016/j.msard.2023.104880Q2N/A